Tampa, FL—Sirion Therapeutics Inc. agreed to receive exclusive U.S. licensing rights to a topical ophthalmic emulsion containing difluprednate, a steroid compound that may treat inflammatory eye diseases.
Eli Lilly and Co. and Alcon Laboratories have reached an agreement to co-promote ruboxistaurin mesylate (proposed brand name, Arxxant) in the United States and Puerto Rico. The agreement is contingent upon FDA approval. The government agency is currently reviewing the oral drug as a treatment for moderate-to-severe nonproliferative diabetic retinopathy.
ISTA Pharmaceuticals filed a New Drug Application for its investigational tobramycin and prednisolone acetate in a fixed combination (T-Pred). The company hopes the drug receives approval as a treatment for inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial ocular infections or a risk of bacterial infections exists.
Philadelphia—Acuity Pharmaceuticals and ZaBeCor Pharmaceutical Co. entered into a license option agreement in which Acuity gains exclusive development and commercialization rights to ophthalmic applications of a small interfering RNA (siRNA).
Retinal specialists have a new therapy in their armamentarium for treating patients with neovascular age-related macular degeneration (AMD).
Identifying and prescribing the optimum non-steroidal anti-inflammatory drug (NSAID) to help patients get the best possible LASEK result is a crucial part of the surgical treatment plan. Likewise, postoperative non-compliance can weaken the outcome of an otherwise perfect procedure.
Fort Lauderdale, FL—An investigational longacting solution of 1.0% azithromycin (AzaSite, InSite Vision) is safe, well tolerated, and effective for the treatment of bacterial conjunctivitis in pediatric patients and adults, according to the results of pivotal phase III clinical trial involving placebo and active controls.
ISTA Pharmaceuticals gained exclusive North American rights to Senju Pharmaceuticals' iganidipine, a calcium-channel blocker, and a new formulation of latanoprost, a prostaglandin analogue.
Compared with placebo, ruboxistaurin mesylate ( proposed brand name , Arxxant, Eli Lilly and Co.) reduces the risk of sustained moderate vision loss by 41% in patients with moderate-to-severe nonproliferative diabetic retinopathy, according to pooled data from two 3-year phase III trials. Eli Lilly and Co. presented the findings at the American Diabetes Association's annual scientific sessions recently.